19 citations
,
September 2008 in “Journal of Cellular Physiology” This article explores potential mechanisms of acneiform skin eruptions linked to EGFR inhibition in cancer patients, focusing on EGFR's role in controlling IL-1-dependent inflammation at hair follicles, but reports no clinical results.
68 citations
,
January 2014 in “Dermatology research and practice” This review discusses the presentation and management of skin toxicity from epidermal growth factor inhibitors, highlighting a correlation between cutaneous adverse effects and tumor response, but reports no new clinical results.
32 citations
,
January 2012 in “International Journal of Dermatology” This study reported that the most common skin side effect of epidermal growth factor receptor inhibitors was a papulopustular rash, treatable with symptom-targeted therapies, while drug suspension was rarely needed.
18 citations
,
July 2008 in “Current Oncology Reports” EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
This study in mice found that a monoclonal antibody targeting EGFR resulted in skin inflammation mediated by TNFα, suggesting potential pathways for addressing EGFR antibody-induced skin rash in cancer patients.